Article Details

Chinese I/O player Adlai Nortye wraps $50M Series B; Amgen touts PhIII data for Remicade knockoff

Retrieved on: 2018-06-26 22:37:30

Tags for this article:

Click the tags to see associated articles and topics

Chinese I/O player Adlai Nortye wraps $50M Series B; Amgen touts PhIII data for Remicade knockoff. View article details on hiswai:

Excerpt

<div>Yuanming Capital led the Series B round, joined by <b>Matrix Partners</b> China, Detong Capital and Yahui Precision Medicine Fund. Adlai Nortye jumped ...</div>

Article found on:

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up